To hear about similar clinical trials, please enter your email below
Trial Title:
Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens
NCT ID:
NCT05498168
Condition:
Esophageal Cancer
Neoantigen
Conditions: Official terms:
Esophageal Neoplasms
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Genetic
Intervention name:
ratio of predicted neoantigens
Description:
10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue
samples (~ 1cm3 ) are collected during surgery
Summary:
This study is to develop computational pipelines and experimental validation assays for
improving the identification of neoantigens from patients with esophageal cancer.
Detailed description:
Esophageal cancer (EC) is the common malignant tumor with poor survival. The long-term
surival rate of patients with advanced EC stages has not been improved with
multidisciplinary treatments including surgery and chemotherapy and radiation. Recently,
immunotherapy approaches using checkpoint inhibitors (CPI), cancer vaccine, and adoptive
T cell therapy have improved survival outcomes of EC patients. The clinical outcomes are
associated with expression levels as well as the immunogenicity of neoantigens which
arise from soma mutations. Therefore, the identification of immunogenic neoantigens is
essential for achieving effective therapies. Recent data published by the Tumor
Neoantigen Selection Alliance (TESLA) show that the majority (98%) of predicted
neoantigens are lack of immunogenicity and ineffective in activating antitumor immune
responses. In our study, we aim to develop a pipeline with both computational prediction
tools and experimental validation assays to enhance the accuracy of neoantigen
identification.
Criteria for eligibility:
Study pop:
All the patients who were diagnosed with adavanced esophageal cancer and underwent
surgical resection
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Male or Female patients aged 18 years and older
2. Diagnosed with advanced esophageal cancer
3. Treatment-Naive
4. Not known for other concomitant cancers
5. Provide written informed consent
Exclusion Criteria:
1. Insufficient tumor tissues (less than 1 cm3 )
2. Unable to sign informed consent
3. Underwent treatment
Gender:
All
Minimum age:
15 Years
Maximum age:
90 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
University Medical Center Ho Chi Minh City
Address:
City:
Ho Chi Minh City
Zip:
700000
Country:
Vietnam
Start date:
September 1, 2022
Completion date:
December 31, 2023
Lead sponsor:
Agency:
University Medical Center Ho Chi Minh City (UMC)
Agency class:
Other
Source:
University Medical Center Ho Chi Minh City (UMC)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05498168